Eliem Therapeutics, Inc stock is up 0.39% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November.
Eliem Therapeutics, Inc. focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy and depression.